

Recombinant Human IGF-BP7
Catalog # PBG10176**Specification**

Recombinant Human IGF-BP7 - Product Information**Recombinant Human IGF-BP7 - Additional Information****Description**

IGF-BPs controls the distribution, function and activity of IGFs in various cell tissues and body fluids. Currently there are seven named IGF-BPs that form high affinity complexes with both IGF-I and IGF-II. IGF-BP7 is expressed in a wide range of normal human tissues and it generally shows reduced expression in cancer cell lines of prostate, breast, colon, and lung origin. It plays a role in skeletal myogenesis by binding to IGF in a manner that inhibits IGF induced differentiation of skeletal myoblasts, without affecting IGF induced proliferation. Additionally, IGF-BP7 suppresses growth and colony formation of prostate and breast cancer cell lines through an IGF independent mechanism, which causes a delay in the G1 phase of the cell cycle, and increased apoptosis. Recombinant human IGF-BP7 is a 26.4 kDa protein consisting of 256 amino acid residues.

BiologicalActivity

Testing In Progress.

Authenticity

Verified by N-terminal and Mass Spectrometry analyses (when applicable).

Endotoxin

Endotoxin level is <0.1 ng/ µg of protein (<1EU/ µg).

Protein Content

Verified by UV Spectroscopy and/or SDS-PAGE gel.

Storage

-20°C

Precautions

Recombinant Human IGF-BP7 is for research use only and not for use in diagnostic or therapeutic procedures.

Recombinant Human IGF-BP7 - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)

- [Flow Cytometry](#)
- [Cell Culture](#)

Recombinant Human IGF-BP7 - Images